Next Article in Journal
Extra-Neural Metastases of Malignant Gliomas: Myth or Reality?
Next Article in Special Issue
Diagnostic Management of Pancreatic Cancer
Previous Article in Journal
Progress in Nanotechnology Based Approaches to Enhance the Potential of Chemopreventive Agents
Previous Article in Special Issue
Pancreatic Cancer Gene Therapy: From Molecular Targets to Delivery Systems
Article Menu

Export Article

Open AccessReview
Cancers 2011, 3(1), 446-460; doi:10.3390/cancers3010446

Metabolic Disorder, Inflammation, and Deregulated Molecular Pathways Converging in Pancreatic Cancer Development: Implications for New Therapeutic Strategies

1
Department of Medical Oncology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan
2
Medical Research Institute, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan
3
Division of Translational & Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
*
Author to whom correspondence should be addressed.
Received: 17 December 2010 / Revised: 18 January 2011 / Accepted: 21 January 2011 / Published: 24 January 2011
(This article belongs to the Special Issue Pancreatic Cancer)
View Full-Text   |   Download PDF [381 KB, 27 January 2011; original version 24 January 2011]   |  

Abstract

Pancreatic cancer develops and progresses through complex, cumulative biological processes involving metabolic disorder, local inflammation, and deregulated molecular pathways. The resulting tumor aggressiveness hampers surgical intervention and renders pancreatic cancer resistant to standard chemotherapy and radiation therapy. Based on these pathologic properties, several therapeutic strategies are being developed to reverse refractory pancreatic cancer. Here, we outline molecular targeting therapies, which are primarily directed against growth factor receptor-type tyrosine kinases deregulated in tumors, but have failed to improve the survival of pancreatic cancer patients. Glycogen synthase kinase-3β (GSK3β) is a member of a serine/threonine protein kinase family that plays a critical role in various cellular pathways. GSK3β has also emerged as a mediator of pathological states, including glucose intolerance, inflammation, and various cancers (e.g., pancreatic cancer). We review recent studies that demonstrate the anti-tumor effects of GSK3β inhibition alone or in combination with chemotherapy and radiation. GSK3β inhibition may exert indirect anti-tumor actions in pancreatic cancer by modulating metabolic disorder and inflammation.
Keywords: pancreatic cancer; glucose intolerance; inflammation; oncogenic pathways; therapeutic target; GSK3β pancreatic cancer; glucose intolerance; inflammation; oncogenic pathways; therapeutic target; GSK3β
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Motoo, Y.; Shimasaki, T.; Ishigaki, Y.; Nakajima, H.; Kawakami, K.; Minamoto, T. Metabolic Disorder, Inflammation, and Deregulated Molecular Pathways Converging in Pancreatic Cancer Development: Implications for New Therapeutic Strategies. Cancers 2011, 3, 446-460.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top